Log in to search using one of your social media accounts:

 

Duzallo (Lesinurad and Allopurinol Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 31, 2017 Category: Drugs & Pharmacology Source Type: news

Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout
Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI). (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced Duzallo was approved by the U.S. Food and Drug Administration (FDA) as a once-daily oral treatment for hyperuricemia associated with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 21, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Clears First Fixed-Dose Combination Treatment for Gout FDA Clears First Fixed-Dose Combination Treatment for Gout
Duzallo combines lesinurad and allopurinol and is indicated for gout-associated hyperuricemia in patients for whom target serum uric acid levels are not achieved with allopurinol alone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Gout Patients Run Higher Risk of Kidney Stones (CME/CE)
(MedPage Today) -- 60% increased risk of first-time nephrolithiasis versus general population, with little protection from allopurinol (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 31, 2017 Category: Geriatrics Source Type: news

Higher Allopurinol Dose Can Safely Lower SU in Gout (CME/CE)
(MedPage Today) -- Dose escalation even tolerated by patients with CKD (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 4, 2017 Category: Consumer Health News Source Type: news

Common yeast may worsen IBD symptoms in Crohn's disease
During the past decade, the gut has experienced a renaissance as investigations focus on the role of the microbiome on human health. While most studies have focused on bacteria, the dominant microbial inhabitants in the gut, scientists used mouse studies to show the role of yeast in aggravating the symptoms of inflammatory bowel disease. Their work suggests that allopurinol, a generic drug already on the market, could offer some relief. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 8, 2017 Category: Science Source Type: news

The Effect of Allopurinol on Renal Function The Effect of Allopurinol on Renal Function
In what ways may treatment with allopurinol impact the kidney?Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Zyloprim (Allopurinol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

Ironwood Announces New Drug Application for Duzallo (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for Duzallo (fixed-dose combination of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 4, 2017 Category: Drugs & Pharmacology Source Type: news

Aloprim (Allopurinol Sodium for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Allopurinol does not increase chronic kidney disease risk in gout patients
(American College of Rheumatology) Allopurinol, a widely used treatment for lowering serum urate levels, does not appear to increase risk of kidney deterioration in gout patients with normal or near-normal kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2016 Category: Global & Universal Source Type: news

Lesinurad Succeeds in Gout (CME/CE)
(MedPage Today) -- Serum urate fell to target levels in twice as many patients compared with allopurinol alone (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 30, 2016 Category: Primary Care Source Type: news

allopurinol
Title: allopurinol Category: Medications Created: 12/31/1997 12:00:00 AM Last Editorial Review: 7/29/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 29, 2016 Category: Rheumatology Source Type: news

Allopurinol Tx Tied to Lower Afib Risk (CME/CE)
(MedPage Today) -- Cohort study suggests cardioprotection from gout drug (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 12, 2016 Category: Cardiology Source Type: news

High-fructose diet during pregnancy may harm placenta, restrict fetal growth
Research in mice and women found that consuming a high-fructose diet during pregnancy may cause defects in the placenta and restrict fetal growth, potentially increasing a baby's risk for metabolic health problems later in life. However, the generic drug allopurinol, frequently prescribed to treat gout and kidney stones, appears to mitigate the negative maternal and fetal effects. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 4, 2016 Category: Science Source Type: news

High-fructose diet during pregnancy may harm placenta, restrict fetal growth
(Washington University in St. Louis) Research in mice and women found that consuming a high-fructose diet during pregnancy may cause defects in the placenta and restrict fetal growth, potentially increasing a baby's risk for metabolic health problems later in life. However, the generic drug allopurinol, frequently prescribed to treat gout and kidney stones, appears to mitigate the negative maternal and fetal effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2016 Category: Global & Universal Source Type: news

AstraZeneca Gives U.S. Rights for Gout Drug to Ironwood Pharma
Agreement includes U.S. rights to ZURAMPIC and lesinurad/allopurinol fixed-dose combination in gout (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 27, 2016 Category: Pharmaceuticals Source Type: news

Allopurinol Hypersensitivity Higher in Blacks, Asians (CME/CE)
(MedPage Today) -- Severe skin toxicity correlates with carriage of the HLA-B*5801 allele (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 15, 2016 Category: Dermatology Source Type: news

Could Coffee Cut the Risk of Gout? (CME/CE)
(MedPage Today) -- It's doubtful that coffee consumption could replace allopurinol (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 29, 2016 Category: Primary Care Source Type: news

New Gout Treatment Effective, Safe in Short Term (CME/CE)
(MedPage Today) -- Lesinurad plus allopurinol significantly increased uric acid clearance (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 12, 2016 Category: Rheumatology Source Type: news

Allopurinol Risky in Asian Population (CME/CE)
(MedPage Today) -- Renal, cardiovascular illness appears to up severe reactions to gout drug. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 22, 2015 Category: Cardiology Source Type: news

No Mortality Risk With Allopurinol in Gout (CME/CE)
(MedPage Today) -- An overall neutral effect seen on deaths from all causes. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 18, 2015 Category: Primary Care Source Type: news

Allopurinol Treat-to-Target Safe in Gout (CME/CE)
(MedPage Today) -- Adverse event rates low, but only a minority reached uric acid target (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 2, 2015 Category: Primary Care Source Type: news

Allopurinol Industry (Global, China) 2015 Research Analysis and 2020...
DeepResearchReports.com announces new research report "2015 Global and China Allopurinol Industry" added to its store.(PRWeb May 29, 2015)Read the full story at http://www.prweb.com/releases/2015-global-china-allopur/market-research-report/prweb12755089.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 30, 2015 Category: Pharmaceuticals Source Type: news

Febuxostat More Effective Than Allopurinol at Usual DosesFebuxostat More Effective Than Allopurinol at Usual Doses
At commonly used doses, febuxostat was more effective than allopurinol at reducing serum uric acid in patients with gout, but allopurinol was likely underdosed. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 27, 2015 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Can Allopurinol Reduce Heart Attack Risk?Can Allopurinol Reduce Heart Attack Risk?
Dr Deane reviews and comments on a recent study looking at the association between use of allopurinol and risk for myocardial infarction. Medscape Rheumatology (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - May 21, 2015 Category: Rheumatology Tags: Rheumatology Viewpoint Source Type: news

Impact of Allopurinol on Risk of Myocardial InfarctionImpact of Allopurinol on Risk of Myocardial Infarction
How does allopurinol affect risk for myocardial infarction? Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2015 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Allopurinol Doesn't Worsen Acute Gout Attacks (CME/CE)
(MedPage Today) -- Worries that it might prove unfounded in randomized trial. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - April 10, 2015 Category: Rheumatology Source Type: news

Allopurinol Doesn?t Worsen Acute Gout Attacks (CME/CE)
(MedPage Today) -- Worries that it might prove unfounded in randomized trial. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 9, 2015 Category: Geriatrics Source Type: news

Allopurinol May Cut MI Risk in Gout Patients (CME/CE)
(MedPage Today) -- Reduction of 20% in myocardial infarction risk; randomized trials are now warranted. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 9, 2015 Category: Cardiology Source Type: news

Reconsidering Allopurinol for HypertensionReconsidering Allopurinol for Hypertension
Henry Black explains why we should proceed with caution when it comes to the use of allopurinol in hypertension management. Medscape Cardiology (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 2, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Risk Factors for Toxicity to AllopurinolRisk Factors for Toxicity to Allopurinol
A study addresses the question: Which patients should not receive allopurinol? Medscape Rheumatology (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 3, 2014 Category: Drugs & Pharmacology Tags: Rheumatology Viewpoint Source Type: news

Comparing allopurinol and febuxostat in gout management
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2014 Category: Drugs & Pharmacology Source Type: news

allopurinol
Title: allopurinolCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 10/8/2014 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 8, 2014 Category: Rheumatology Source Type: news

RheumShorts: Allipurinol, Autoantibodies in RA (CME/CE)
(MedPage Today) -- The rheumatology literature this week featured studies on allopurinol and severe cutaneous adverse reactions, the additive effects of autoantibodies on bone erosions in rheumatoid arthritis, and predicting response to methotrexate in children with juvenile idiopathic arthritis. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 20, 2014 Category: Primary Care Source Type: news

RheumShorts: Allopurinol; Autoantibodies in RA (CME/CE)
(MedPage Today) -- The rheumatology literature this week featured studies on allopurinol and severe cutaneous adverse reactions, the additive effects of autoantibodies on bone erosions in rheumatoid arthritis, and predicting response to methotrexate in children with juvenile idiopathic arthritis. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 20, 2014 Category: Rheumatology Source Type: news

Gout drug may reduce risk of death
In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout) patients. The study, the first in a general population, has found the overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects.Researchers from the Section of Rheumatology and Clinical Epidemiology at Boston University School of Medicine (BUSM) contributed to this study.Gout has been associated with an increased risk of premature death. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 26, 2014 Category: Consumer Health News Tags: Gout Source Type: news

Less than half of gout patients reach recommended treatment goal following treatment with allopurinol
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, 6-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol. Results of the LASSO study showed no new safety signals with allopurinol doses of approximately 300mg/day... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 31, 2013 Category: Consumer Health News Tags: Gout Source Type: news

A large, observational study of common gout treatment allopurinol shows less than half of patients reach recommended treatment goal
(Edelman Public Relations) AstraZeneca and Ardea Biosciences today presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, six-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2013 Category: Global & Universal Source Type: news

Gout: No Help From Vitamin C Gout: No Help From Vitamin C
In patients with gout, vitamin C supplementation at 500 mg/day, either alone or with allopurinol, did not reduce uric acid levels enough to be clinically significant. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Vitamin C No Help in Gout (CME/CE)
(MedPage Today) -- Vitamin C supplements didn't lower uric acid levels in patients with gout when given either alone or in combination with allopurinol, an open-label pilot study showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 16, 2013 Category: Consumer Health News Source Type: news

Vitamin C Does Not Lower Uric Acid Levels In Gout Patients
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 16, 2013 Category: Consumer Health News Tags: Gout Source Type: news

Vitamin C does not lower uric acid levels in gout patients
(Wiley) Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology journal, Arthritis & Rheumatism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2013 Category: Global & Universal Source Type: news

Allopurinol: Severe Cutaneous Reactions Rare but Serious Allopurinol: Severe Cutaneous Reactions Rare but Serious
Severe cutaneous reactions requiring hospitalization are rare but occurred 10 times more often among patients beginning allopurinol treatment, and most often in the first 180 days of use. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news

RCT: High-dose allopurinol reduces left ventricular mass in patients with ischaemic heart disease
Source: J Am Coll Cardiol Area: News Left ventricular hypertrophy (LVH) is common in patients with IHD including normotensive patients. Allopurinol, a xanthine oxidase inhibitor, has been shown to reduce LV afterload in IHD and may therefore also regress LVH. This randomised placebo-controlled study sought to ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in patients with ischemic heart disease (IHD). Sixty six patients with IHD and LVH were randomised to either 600mg allopurinol daily or placebo for 9 months. The primary outcome measure was change in LVM, assessed by cardiac magnetic resonance i...
Source: NeLM - Cardiovascular Medicine - March 8, 2013 Category: Cardiology Source Type: news